Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Danapha Pharmaceutical JSCHSTC:DAN 31 Debt-to-EBITDA is 0.00 as of . 20. GuruFocus rates HSTC:DAN with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 690 Drug Manufacturers companies, Danapha Pharmaceutical JSC ranks worse than 144927.39% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Danapha Pharmaceutical JSC's Debt-to-EBITDA or its related term are showing as below:
HSTC:DAN's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.65 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Danapha Pharmaceutical JSC Debt-to-EBITDA Related Terms
Danapha Pharmaceutical JSC Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Danapha Pharmaceutical JSC Debt-to-EBITDA Chart
Danapha Pharmaceutical JSC Annual Data
Trend
Debt-to-EBITDA
Danapha Pharmaceutical JSC Semi-Annual Data
Debt-to-EBITDA
HSTC:DAN vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Danapha Pharmaceutical JSC's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Danapha Pharmaceutical JSC Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Danapha Pharmaceutical JSC's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Danapha Pharmaceutical JSC's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is one times the quarterly (. 20) EBITDA data.
Danapha Pharmaceutical JSC (HSTC:DAN) has a Debt-to-EBITDA of 0.00 as of . 20. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Danapha Pharmaceutical JSC. According to the industry distribution chart, Danapha Pharmaceutical JSC ranks #999999 out of 690 companies in the Drug Manufacturers industry.
Is Danapha Pharmaceutical JSC's Debt-to-EBITDA too high?
Danapha Pharmaceutical JSC's current Debt-to-EBITDA is 0.00. Based on the distribution chart, Danapha Pharmaceutical JSC ranks #999999 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Danapha Pharmaceutical JSC has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Danapha Pharmaceutical JSC's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Danapha Pharmaceutical JSC ranks #999999 out of 690 companies for Debt-to-EBITDA. This places Danapha Pharmaceutical JSC in the lower half of its industry. The industry median Debt-to-EBITDA is 1.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.65, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Danapha Pharmaceutical JSC. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Danapha Pharmaceutical JSC's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Danapha Pharmaceutical JSC stock overvalued right now?
Danapha Pharmaceutical JSC (HSTC:DAN) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Danapha Pharmaceutical JSC's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Danapha Pharmaceutical JSC (HSTC:DAN), the current Debt-to-EBITDA is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Danapha Pharmaceutical JSC is a manufacturer of herbal medicine and specific drugs such as central nervous system, neurotonics, anti-diabetics, cardiovascular drug, gastrointestinal and heaptic biliary system with forms such as tablets, capsules, injection, sirup, balm and medicated oil.
31GF Score
Get the complete analysis for HSTC:DAN
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSTC:DAN has been successfully added to your 
